The capsule physically separates the different tissues from each other and allows them to exchange soluble factors, similar to how organs interact through blood circulation in the human body. Encapsulated cells aggregate within a few days to form spheroids. The capsule controls the size of the spheroid to ensure oxygen and nutrient diffusion, similar to perfused tissues.
A unique color-coded capsule is assigned to each tissue type so that separate tissues can be recognized without labeling the cells in a multi-tissue culture.
A set of readouts evaluating cytotoxicity and tissue-specific effects were calibrated in-house to provide a robust evaluation of drug effects with several parameters assessed simultaneously.
The strong capability of FluoSphera technology to fit with existing consumables and instruments, along with an automated analysis pipeline for high-content imaging and color multiplexing for tissue and effects identification, allows fast evaluation of compound libraries to provide human-system-relevant datasets.
Variabilities between organoids can generate biased analyses. The spatial positioning of FluoSphera technology allows tracking individual organoids within a pool to understand drug effects before and after treatment, generating unbiased datasets.
After imaging used for drug effect identification, tissues can be sequentially sorted to isolate them for omics downstream assays. This approach provides a holistic view of the drug's mode of action by correlating phenotypic analyses with genomic, proteomic, and lipid profiling.
FluoSphera's technology is a multi-organoid system that combines encapsulated tissues to mimic the complex human system, enabling reliable in vitro drug discovery.